RT Journal Article
SR Electronic
T1 Precision Medicine Approach to Alzheimer’s Disease: Successful Proof-of-Concept Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.10.21256982
DO 10.1101/2021.05.10.21256982
A1 Toups, Kat
A1 Hathaway, Ann
A1 Gordon, Deborah
A1 Chung, Henrianna
A1 Raji, Cyrus
A1 Boyd, Alan
A1 Hill, Benjamin D.
A1 Hausman-Cohen, Sharon
A1 Attarha, Mouna
A1 Chwa, Won Jong
A1 Jarrett, Michael
A1 Bredesen, Dale E.
YR 2021
UL http://medrxiv.org/content/early/2021/05/11/2021.05.10.21256982.abstract
AB Importance Effective therapeutics for Alzheimer’s disease and mild cognitive impairment are needed.Objective To determine whether a precision medicine approach to Alzheimer’s disease and mild cognitive impairment, in which potential contributors to cognitive decline are identified and targeted therapeutically, is effective enough in a proof-of-concept trial to warrant a larger, randomized, controlled clinical trial.Rationale Previous clinical trials for Alzheimer’s disease have pre-determined a single treatment modality, such as a drug candidate or therapeutic procedure, that may be unrelated to the primary drivers of the neurodegenerative process. Therefore, increasing data set size to include the potential contributors to cognitive decline for each patient, and addressing the identified potential contributors, may represent a more effective therapeutic strategy.Hypothesis Alzheimer’s disease is a multi-factorial network dysfunction that results from a chronic or repeated insufficiency of support for a neuroplasticity network; thus factors that increase demand—such as infections or toxin exposure—or reduce support—such as reduced energetics or trophic support—may contribute to the neurodegenerative process. Rectifying this hypothesized network dysfunction represents a rational approach to the treatment of the cognitive decline associated with Alzheimer’s disease and mild cognitive impairment.Design Twenty-five patients with Alzheimer’s disease or mild cognitive impairment, with Montreal Cognitive Assessment (MoCA) scores of 19 or higher, were evaluated for markers of inflammation, chronic infection, dysbiosis, insulin resistance, protein glycation, vascular disease, nocturnal hypoxemia, hormone insufficiency or dysregulation, nutrient deficiency, toxin or toxicant exposure (metals, organic toxicants, and biotoxins), genetic predisposition to cognitive decline, and other biochemical parameters associated with cognitive decline. Brain magnetic resonance imaging with volumetrics was performed at baseline and study conclusion. Patients were treated for nine months with a personalized, precision medicine protocol that addressed each patient’s identified potentially contributory factors, and cognition was assessed at t = 0, 3, 6, and 9 months.Trial registration and IRB approval The clinical trial was registered at clinicaltrials.gov (NCT03883633),1 and approved by the Advarra IRB.Support for the trial The trial was supported by a grant from the Four Winds Foundation via Evanthea, LLC, and we are grateful to Diana Merriam and Gayle Brown for their interest, discussions, and support.Main Outcome Measures Trained external raters evaluated the study subjects with the Montreal Cognitive Assessment (MoCA), CNS Vital Signs (a computerized cognitive assessment battery), AQ-21 (a subjective scale completed by the significant other or study partner), and AQ-C change scale (a subjective scale of cognitive improvement or decline, completed by the significant other or study partner). Follow-up brain MRI with volumetrics was carried out at the completion of the trial.Results All outcome measures revealed improvement: statistically highly significant improvement in MoCA scores, CNS Vital Signs Neurocognitive Index, and AQ-C were documented. No serious adverse events were recorded.Conclusions and Relevance Based on the cognitive improvements observed in this study of patients with Alzheimer’s disease or mild cognitive impairment, a larger, randomized, controlled trial of the precision medicine therapeutic approach described herein is warranted.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03883633Funding StatementFunding was from the Four Winds Foundation, a non-profit entity. No additional funds were obtained. The funding entity had no role whatsoever in the planning, execution, analysis, or reporting of the results. None of the authors received compensation for the study except from the Foundation, to the 3 performing physicians (for seeing the patients) and the CRO (Quesgen). The remainder of the authors received no support for the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This manuscript describes a clinical trial that is registered at clinicaltrials.gov (NCT03883633) and has been approved by the Advarra IRB. All relevant ethical guidelines have been followed, all necessary patient consents obtained, and the trial has been completed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data (de-identified) in the manuscript are publicly available.